-

Brian O’Donnelly Appointed to Expanded Role, Strengthening Global Leadership to Drive Growth in the Fujifilm’s Electronic Materials Business

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that the company has appointed Brian O’Donnelly as its Corporate Vice President, strengthening global leadership to drive growth in the Electronic Materials Business. He will continue serving as the President and CEO of FUJIFILM Electronic Materials USA, Inc., Senior Deputy General Manager of the Electronic Materials Business Division, FUJIFILM Corporation and Global Vice President of FUJIFILM Electronic Materials.

Born and educated in Scotland, O’Donnelly has spent the majority of his 40-year career working in the Chemical and Semiconductor Materials industries, joining Fujifilm group in 2004. In 2014, he was appointed President and CEO of FUJIFILM Electronic Materials USA, where he has led significant growth of the business and its contributions to Fujifilm through new product development, customer and product portfolio expansions, and mergers and acquisitions.

“Brian is a strong leader who has long contributed to the development of the Fujifilm’s Electronic Materials business, not just in North America, but also globally through strategic acquisitions and integrations that have allowed us to expand our portfolio of products and services to meet the needs of the world’s top semiconductor manufacturers,” said Tetsuya Iwasaki, Director, Senior Vice President and General Manager of the Electronic Materials Business Division, who leads the global business.

Prior to joining Fujifilm, O’Donnelly worked for Olin Corporation’s Materials Metal Research Labs in R&D, as well as Arch Chemicals, where he held progressively more senior roles in finance, strategic planning, M&A and business management within its Chemicals and Electronic Materials Divisions.

“I am looking forward to continuing to help our global business realize its full growth potential and be the leading and most trusted Electronic Materials partner in the global semiconductor industry,” said O’Donnelly. “As Corporate Vice President at FUJIFILM Corporation, I am honored to contribute to the company’s commitment to global diversity and to be part of an inclusive leadership culture that reflects our expanding global business portfolio.”

O’Donnelly holds a PhD in Metallurgy from the University of Strathclyde in Glasgow, Scotland. He earned his MBA in Finance & Strategy Planning from the University of New Haven in Connecticut.

About Fujifilm

FUJIFILM Electronic Materials, U.S.A., Inc. is a wholly owned subsidiary of FUJIFILM Holdings America Corporation. FUJIFILM Electronic Materials, U.S.A., Inc. supplies the world's top semiconductor manufacturers with a broad array of products and services, including chemicals and advanced materials. The company’s broad product portfolio includes high-purity acids/bases, photoresists, thin film formation materials, formulated products, CMP slurries, and polyimides for advanced packaging. The company has six state-of-the-art manufacturing facilities and research labs in the U.S., including Arizona, California, Colorado, Rhode Island, and Texas. For more information, please visit: https://www.fujifilm.com/em-global/en.

FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of “giving our world more smiles,” we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.

For further details about our commitment to sustainability and Fujifilm’s Sustainable Value Plan 2030, click here.

Contacts

Media Contacts

Michele Darnell
FUJIFILM Holdings America Corporation
E-mail: michele.darnell@fujifilm.com

FUJIFILM Corporation


Release Versions

Contacts

Media Contacts

Michele Darnell
FUJIFILM Holdings America Corporation
E-mail: michele.darnell@fujifilm.com

More News From FUJIFILM Corporation

Fujifilm Announces Firmware Roadmap for FUJIFILM GFX ETERNA 55 Filmmaking Camera

TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation today announces a firmware roadmap designed to further expand the applications of the “FUJIFILM GFX ETERNA 55” (GFX ETERNA 55), Fujifilm’s first dedicated filmmaking camera. The latest update expands the possibilities for creative work and further enhances expressive capabilities. Ver.1.101 – Available July 15, 2026 The camera’s overall operational stability and usability have been updated to provide a refined shooting experience. Ver.1.20 or later –...

Fujifilm Adds Second Cinema Power Zoom to GF Lens Lineup: FUJINON GF19-35mmT3.5 PZ OIS WR

VALHALLA, N.Y.--(BUSINESS WIRE)--FUJIFILM North America Corporation, Electronic Imaging Division, today announced the release of FUJINON GF19-35mmT3.5 PZ OIS WR (“GF19-35mmT3.5”), the second FUJINON cinema power zoom lens for the GFX System. With a native G Mount, GF19-35mmT3.5 provides the widest angle of view available in the GF format, offering filmmakers at all levels of production a large format cinema zoom with expanded cinematic versatility and exceptional optical performance in a compac...

FUJIFILM Biotechnologies Selected in FDA PreCheck Pilot Program to Advance U.S. Drug Manufacturing

HOLLY SPRINGS, N.C.--(BUSINESS WIRE)--FUJIFILM Biotechnologies (Fujifilm), a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced that its commercial-scale cell culture manufacturing facility in Holly Springs, North Carolina, has been selected as one of only seven participants in the U.S. Food and Drug Administration's (FDA) PreCheck Pilot Program. The program is a strategic initiative designed to strengthen Am...
Back to Newsroom